CareDx to Acquire Naveris, Expanding Leadership in Viral-Driven Cancer MRD Surveillance Testing
CareDx, Inc., widely recognized for its focus on advancing precision medicine solutions in transplant care, has taken a significant strategic step to broaden its reach into oncology diagnostics. The company announced that it has entered into a definitive agreement to acquire Naveris, a commercial-stage innovator specializing in blood-based monitoring technologies for viral-mediated cancers. This acquisition reflects CareDx’s continued commitment to expanding its capabilities in high-value healthcare solutions while leveraging its expertise in molecular diagnostics, patient monitoring, and digital health integration.
Under the terms of the agreement, CareDx will provide an upfront cash payment of $160 million, with the potential for an additional $100 million contingent upon the achievement of specified revenue milestones. The deal underscores CareDx’s intention to strengthen its presence in the U.S. Precision Medicine Testing Services market while simultaneously enhancing its Patient and Digital Solutions portfolio. By integrating Naveris’ advanced oncology diagnostics platform, CareDx aims to diversify its offerings beyond transplant medicine and capitalize on the growing demand for non-invasive cancer monitoring technologies.
At the core of Naveris’ innovation is its proprietary Tumor Tissue Modified Viral (TTMV®) DNA platform, a highly differentiated liquid biopsy technology designed to detect and monitor viral-associated cancers. This approach works by identifying fragments of viral DNA that are shed by tumor tissue into the bloodstream. These circulating biomarkers provide clinicians with a powerful and precise tool for detecting disease presence and progression, particularly in cancers driven by viruses such as human papillomavirus (HPV). The ability to measure tumor-derived viral DNA in a minimally invasive manner represents a significant advancement over traditional diagnostic methods, which often rely on imaging or tissue biopsies.
One of the most compelling aspects of Naveris’ platform is its tumor-naïve testing capability. Unlike many conventional diagnostic tools that require prior knowledge of tumor-specific mutations, Naveris’ technology can be used from the point of diagnosis through post-treatment monitoring without needing an initial tumor sample. This enables clinicians to track molecular residual disease (MRD) and detect recurrence earlier, offering the potential to improve patient outcomes through timely intervention. The platform has gained particular traction in the management of head and neck cancers and anal cancers, where HPV plays a prominent role in disease development.
Financially, Naveris has demonstrated strong growth and promising performance metrics, further validating the strategic rationale for the acquisition. The company reported unaudited revenue of $34 million for the full year 2025 and is projected to achieve an annual growth rate of 30% to 40% over the next three years. In the first quarter of 2026 alone, Naveris generated approximately $12 million in revenue, with gross margins reaching 65%. Notably, the company maintained a near break-even position with a net operating loss of just $0.2 million during the quarter. These figures indicate a scalable business model with improving operational efficiency, making Naveris an attractive addition to CareDx’s portfolio.
CareDx has indicated that the acquisition is not expected to impact its Adjusted EBITDA (AEBITDA) guidance for 2026. The company plans to provide more detailed financial projections and integration updates following the closing of the transaction. This disciplined financial approach suggests that CareDx is prioritizing long-term value creation while maintaining short-term financial stability.
Leadership from both organizations has expressed strong enthusiasm about the transaction and its potential to reshape the future of precision medicine. John Hanna, President and Chief Executive Officer of CareDx, emphasized that the acquisition aligns with the company’s broader growth strategy. He highlighted the importance of focusing on specialized markets characterized by a high burden of disease and a need for repeat diagnostic testing. According to Hanna, Naveris fits this profile perfectly, offering a differentiated technology that is still in the early stages of adoption but poised for rapid expansion.
Hanna also pointed to CareDx’s core strengths as key enablers of Naveris’ future growth. These include the company’s ability to build clinical confidence in molecular testing, streamline workflows for healthcare providers, and generate robust clinical evidence to support coverage and reimbursement. By applying these capabilities to Naveris’ platform, CareDx aims to accelerate market adoption and expand patient access to cutting-edge diagnostic tools.
From Naveris’ perspective, the acquisition represents an opportunity to scale its technology and amplify its impact on patient care. James B. McNally, Chief Executive Officer of Naveris, noted that the company has successfully developed and commercialized a liquid biopsy platform capable of detecting cancer earlier and more accurately than traditional approaches. He expressed optimism about joining forces with CareDx, citing the shared mission of improving patient outcomes through innovative and disruptive technologies. McNally also emphasized the potential to expand access to precision medicine, ensuring that more patients can benefit from advanced diagnostic solutions.
Operationally, Naveris brings a well-established infrastructure to the combined organization. The company employs approximately 100 individuals and has already conducted more than 130,000 commercial tests, demonstrating significant market penetration and clinical adoption. Importantly, its flagship test received Medicare coverage in 2023, a milestone that has played a crucial role in driving utilization and revenue growth. Reimbursement from Medicare not only validates the clinical utility of the test but also enhances its accessibility for a broader patient population.
The acquisition is expected to close in the third quarter of 2026, subject to customary closing conditions, including regulatory approvals. Both companies have engaged leading financial and legal advisors to support the transaction. Goldman Sachs is serving as the exclusive financial advisor to CareDx, with Fenwick & West acting as its legal counsel. On the other side, J.P. Morgan Securities LLC is advising Naveris financially, while Skadden, Arps, Slate, Meagher & Flom LLP is providing legal guidance.
Strategically, this transaction reflects a broader trend within the healthcare and biotechnology sectors, where companies are increasingly investing in precision diagnostics and liquid biopsy technologies. These tools are transforming the way diseases are detected, monitored, and managed, shifting the paradigm from reactive treatment to proactive and personalized care. By acquiring Naveris, CareDx is positioning itself at the forefront of this تحول, expanding its capabilities beyond transplant diagnostics into the rapidly growing field of oncology.
The integration of Naveris’ platform into CareDx’s ecosystem is expected to create synergies across multiple dimensions. These include leveraging CareDx’s commercial infrastructure to drive adoption, integrating digital health solutions to enhance patient engagement, and utilizing data analytics to generate insights that support clinical decision-making. Together, these capabilities could enable a more comprehensive approach to patient care, spanning diagnosis, treatment, and long-term monitoring.
In conclusion, the acquisition of Naveris represents a transformative step for CareDx as it seeks to broaden its impact in precision medicine. By combining its established expertise in transplant diagnostics with Naveris’ innovative oncology platform, the company is well-positioned to address unmet needs in cancer care and deliver value to patients, providers, and stakeholders alike. As the healthcare landscape continues to evolve, strategic moves such as this highlight the growing importance of integrated, data-driven solutions in improving outcomes and advancing the future of medicine.
About CareDx
CareDx is a precision medicine company dedicated to improving outcomes for transplant patients and advancing organ health. The Company’s integrated solutions include non‑invasive molecular testing for heart, kidney, and lung transplants; laboratory products; digital health technologies; and patient solutions that support care before and after transplant. CareDx is the leading provider of genomics‑based information for transplant patients. For more information, please visit www.caredx.com.
About Naveris
A portfolio company of B-FLEXION Life Sciences, Naveris is a privately held, commercial-stage precision oncology diagnostics company focused on improving outcomes for patients with viral-driven cancers. Founded in 2017, the Company develops and commercializes novel molecular diagnostics designed to enable earlier cancer detection and more personalized disease management. Naveris’ proprietary NavDx® test is a clinically validated circulating tumor DNA blood test that detects tumor tissue–modified viral (TTMV®) HPV DNA to support post-treatment surveillance and molecular residual disease (MRD) assessment in HPV-driven cancers. The Company operates high-complexity clinical laboratories in Massachusetts and North Carolina that are accredited by the College of American Pathologists and the New York State Department of Health Wadsworth Center and certified under CLIA.
Source Link:https://www.businesswire.com/
